BioFuse™ is a new RF tissue sealing and welding technology. Using transformative technology which is proven in Europe in 1000’s of cases, this surgical innovation replaces traditional methods of sutures, staples and electrosurgical vessel sealing.
Biofuse Technology
Can address a broad range of clinical applications in many disciplines
Has a robust pipeline of products in various stages of development.
Already has an FDA 510(k) clearance for vessel sealing, solid IP protection and an arsenal of trade secrets
Market Data
This technology is serving a large and growing target market of $3 billion. Market Data indicates a strong and growing demand for advanced, innovative devices that facilitate evolving surgical procedural techniques and vastly improve patient outcomes. Surgeons are looking for the new solutions, the new technology that will eliminate scars and lower infection rates.
There is also an increased demand to replace or monitor staples that are under recall. An FDA report from March 2019 indicated 41,000 ‘adverse event reports’ for staplers from 2011 – 2018. There is also a continued focus on MIS to reduce hospital stays and thereby reduce hospital costs for the patients.
Technology
BioFuse Technology addresses the clinical challenges that surgeons face by delivering sophisticated, advanced algorithm-controlled energy to surgical instruments.
The Technology Promotes:
Leak Proof continuous tissue to tissue connection
Revascularization to improve blood flow
Technology Lowers OR Time
Company’s Keywords:
surgical oncology, general surgery, colorectal, bariatric, urology, gynecology, ophthalmology, orthopaedics, thoracic, hepatobiliary, transplant, trauma, plastics, reconstructive, veterinary
<6
<
<2013
Your request has been submitted successfully.
Own or work here?